Stadler Ellen V, Holmes Alison, O'Hare Danny, Rawson Timothy M
Centre for Antimicrobial Optimisation, Imperial College London, London, UK.
Department of Infectious Diseases, Imperial College London, London, UK.
Commun Med (Lond). 2025 Jul 1;5(1):263. doi: 10.1038/s43856-025-00962-z.
Monitoring host- and pathogen-specific biomarkers alongside drug levels at the site of infection offers promise for personalised antimicrobial therapy. Here, we highlight the potential of longitudinally monitoring biomarkers in urine using existing technologies to enable individualised PK-PD optimisation in urinary tract infections.
在感染部位监测宿主和病原体特异性生物标志物以及药物水平，为个性化抗菌治疗带来了希望。在此，我们强调利用现有技术纵向监测尿液中的生物标志物，以实现尿路感染中个体化药代动力学-药效学优化的潜力。
